Cambridge, Mass.-based Selventa, a personalized healthcare company focused on development of predictive biomarker panels, has formed a multi-year research agreement with Janssen R&D in immunological disease.

The agreement focuses on development of disease models using diverse biologic data to elaborate disease-relevant mechanisms and identify potential new drug discovery opportunities.

“We are very excited to have the opportunity to continue to work with Janssen R&D,” said David de Graaf, president and CEO of Selventa. “Building comprehensive disease models and investigating different molecular mechanisms may provide key data-driven foundations for appropriate selection of druggable mechanisms within a disease.”

Selventa utilizes molecular patient data and computational methods to derive mechanistic understanding of disease biology and unambiguously identify patient subsets based on their disease-driving mechanisms to enable personalized healthcare. This includes assessment of single and combination therapies, segmentation of potential responder and non-responder populations, evaluation of alternative indications, and optimization of proof-of-concept clinical trial design through stratification biomarker panels.